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ABSTRACT
Rho GTPases play central roles in a wide variety of cellular processes, including cytoskeletal
dynamics, cell adhesion and cell polarity. RhoU and RhoV are Rho GTPases that have some atypical
properties compared with classical Rho family members, such as the presence of N- and C-terminal
extension regions, unusual GDP/GTP cycling and post-translational modiﬁcation by palmitoylation
but not prenylation. Their activity and localization is regulated by the N-terminal and C-terminal
regions, and so far no GEFs or GAPs have been identiﬁed for them. Similar to Rac and Cdc42, they
interact with PAK serine/threonine kinases, and in the case of PAK4, this interaction leads to RhoU
protein stabilization. In cells, RhoU and RhoV alter cell shape and cell adhesion, which probably
underlies some of the phenotypes reported for these proteins in vivo, for example in heart
development and epithelial morphogenesis. However, the molecular basis for these functions of
RhoU and RhoV remains to be characterized.
KEYWORDS
Rho GTPases; RhoU; RhoV;
post-translational
modiﬁcations; signal
transduction; cell adhesion;
cell migration
Introduction
Rho GTPases are a distinct family within the Ras superfam-
ily of small GTPases, based on their structure and function
(Figure 1). Members of the family are present in all eukary-
otic organisms sequenced to date. Rho GTPases are key reg-
ulators of the actin cytoskeleton, and have been shown to
contribute to processes as diverse as cell migration, cell
adhesion, cell polarity, cell division, transcriptional regula-
tion and cell cycle progression.1 In humans there are 20 Rho
GTPase genes, some of which have different splice variants.2
Most Rho GTPases cycle between an active GTP-
bound conformation and an inactive GDP-bound confor-
mation. This cycling is regulated by guanine-nucleotide
exchange factors (GEFs), which stimulate release of GDP,
allowing GTP to bind, and GTPase-activating proteins
(GAPs), which catalyze GTP hydrolysis, hence inactivating
the Rho GTPase. When bound to GTP, they interact with
a range of downstream target proteins to induce cellular
responses. The majority of Rho GTPases are post-transla-
tionally modiﬁed at their C-termini by addition of farnesyl
or geranylgeranyl isoprenoid lipids, which mediate their
interaction with cellular membranes. Some Rho GTPases
also bind to RhoGDIs, which recognize geranylgeranylated
proteins, extracting them from membranes and keeping
them in an inactive complex in the cytosol.
RhoU and RhoV form a distinct subfamily of Rho
GTPases based on their sequence homology (Figure 1).
RhoU and RhoV genes emerged after Rho, Rac and
Cdc42 in evolution: whereas Rho, Rac and/or Cdc42
genes are present in all eukaryotes, RhoU and RhoV are
not found in plants or fungi or all animals, but a RhoU/
RhoV ortholog is present in multiple Coelmate species,
including insects and worms.2 The RhoU and RhoV pro-
teins share 55.4% amino acid identity with each other.
RhoU (also known as Wrch-1: Wnt responsive Cdc42
homolog 1) was ﬁrst cloned as a Wnt-inducible gene
that induced the transformation of mouse mammary
epithelial cells.3 RhoV (also known as Chp: Cdc42Hs
homolog protein) was ﬁrst discovered as a p21-activated
kinase (PAK)2-interacting protein in a yeast 2-hybrid
screen.4 RhoU mRNA appears to be expressed in most
mouse tissues, whereas RhoV has a more restricted
expression proﬁle.2 RhoU and RhoV are considered to
be atypical GTPases because they have several character-
istics that distinguish them from the better characterized
Rho family members such as RhoA, Rac1 and Cdc42.
This review addresses the biochemical regulation and
functions of RhoU and RhoV.
RhoU and RhoV regulation and signaling
Biochemical properties
RhoU is considered to be an atypical GTPase because it
has been reported to have a 10-fold higher intrinsic
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guanine nucleotide exchange rate in vitro compared with
Cdc42, and is therefore presumed to be predominantly
GTP-bound in cells.5,6 By contrast, the biochemical char-
acterization of RhoV GDP/GTP exchange or GTP
hydrolysis has not been reported and therefore it is not
known whether it exchanges GDP for GTP at a similarly
high rate. Due to its homology with RhoU, RhoV is spec-
ulated to be similarly predominantly GTP-bound.7
Role of N-terminal regions in regulating RhoU
and RhoV
RhoU and RhoV have unique N-terminal and C-termi-
nal regions either side of the core GTP-binding domain
(Figures 2 and 3). Among the Rho GTPases, the 3 Rnd
subfamily members also have N-terminal and C-termi-
nal extensions.8
The N-terminal region has been proposed to act as a
negative regulator of both proteins. N-terminal trunca-
tion of RhoU increases anchorage-independent growth
of NIH3T3 ﬁbroblasts and also enhances RhoU associa-
tion with effector proteins.5 The N-terminal region of
RhoU has been shown to inhibit its ability to activate
PAK1, as indicated by PAK1 autophosphorylation.5
However, another study reported that RhoU required
the N-terminal region to induce ﬁlopodia in porcine aor-
tic endothelial (PAE) cells, and this region has proline-
rich regions that bind to several proteins with SH3
domains (Figure 2). Hence, the role of the N-terminal
region is controversial. Deletion of the N-terminal region
does not alter the nucleotide exchange or GTP hydrolysis
activity of RhoU in comparison with Cdc42.5
Similar to RhoU, deletion of the N-terminal region of
RhoV resulted in growth transformation and an increase
in anchorage-independent growth of NIH3T3 ﬁbroblasts
in soft agar.9 Furthermore, N-terminal deletion of RhoV
resulted in the recruitment of a YFP-PAK-CRIB reporter
to endosome structures. This indicates that the active
pool of RhoV is found at endosomes, in contrast to a
report on RhoU that suggested the endosomal pool was
Figure 1. The Rho GTPase family. The 20 Rho GTPases are
grouped into 8 distinct subfamilies based on sequence similarity.
The phylogenetic tree was generated by Clustal Omega software
(EMBL-EBI), using the amino acid sequences of the 20 Rho
GTPases. The sequence of Rac1a and Cdc42 isoform 1 splice var-
iants was used.
Figure 2. RhoU domain structure and protein interactions. RhoU has a core GTP-binding domain (red) and N- and C-terminal extension
regions (gray). Regions that are known to interact with other proteins are indicated in yellow. The N-terminal region contains 3 proline-
rich motifs (PXXP; yellow) which bind to SH3 domains in the indicated proteins. At the C-terminus is a CFV motif (amino acids 256–258)
which is modiﬁed on the cysteine by palmitoylation and is required for membrane localization. The Src tyrosine kinase phosphorylates
Tyr254, which alters RhoU localization. p21-activated kinases (PAKs) are well established RhoU effector proteins which bind to the effec-
tor loop (yellow) of RhoU and regulate cytoskeletal dynamics and cell migration. ARHGAP30, Pyk2 and PAR6 have also been described
to bind to the effector loop by co-immunoprecipitation analysis and these interactions allow RhoU to regulate several cellular functions.
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inactive.10 TNF-a activation was also shown to induce
the activation of RhoV at the endosomal compartment,
but not at the plasma membrane.11
Role of C-terminal regions in sub-cellular
localization
RhoU and RhoV are localized to both the plasma mem-
brane and endomembrane compartments. Both RhoU
and RhoV have been reported to be modiﬁed by C-ter-
minal S-palmitoylation but unlike most other Rho
GTPases are not prenylated9,12 (Figure 2 and 3). S-palmi-
toylation is a post-translational lipid modiﬁcation in
which a 16-carbon fatty acid palmitate group is cova-
lently attached to cysteine residues on target proteins,
and promotes their interaction with membranes.12,13 In
contrast to protein prenylation, palmitoylation is a
reversible enzymatic process. This allows RhoU and
RhoV to associate transiently and dynamically with cel-
lular membranes.9,12 Since RhoU and RhoV are not pre-
nylated and therefore cannot bind RhoGDIs, the
reversible nature of palmitoylation might serve to regu-
late their activity by altering their localization.11,12
In addition to S-palmitoylation, a stretch of polybasic
residues and a tryptophan (W229) close to the C-termi-
nus have been reported to facilitate the membrane locali-
zation and transforming potential of RhoV.11 Mutation
of W229 resulted in localization to the cytoplasm, with
an essentially identical localization pattern to C-termi-
nally deleted RhoV.11 Two arginine residues near the C-
terminus also affect RhoV localization: RhoV-R226Q
and RhoV-R228Q have a slightly reduced plasma mem-
brane localization but still associate with endomem-
branes.11 These C-terminal residues are also important
for the recruitment of effector proteins to speciﬁc mem-
brane sub-cellular locations. Deletion of the C-terminal
region abolished the transforming activity of RhoV, indi-
cating that the C-terminus is essential for its normal
function.9
Src-mediated tyrosine phosphorylation of RhoU has
been shown to regulate its sub-cellular localization.
Phosphorylation of RhoU on a C-terminal tyrosine,
Y254, results in a rapid relocalization of RhoU from the
plasma membrane to the endosomal compartment.10
This was also associated with a decrease in GTP binding,
and thus it was argued that the endosomal pool of RhoU
is inactive. This was speculated to be due to altering its
proximity to GEFs and GAPs, with a concomitant
decrease in effector protein interactions.10 However, a
separate study found that the RhoU-Y254F mutant was
not phosphorylated by Src as expected but was still capa-
ble of localizing on endosomes.14 These 2 studies were
performed in different cell types, and thus the contribu-
tion of tyrosine phosphorylation to RhoU localization
might be cell-type dependent. Further studies are there-
fore required to determine how RhoU phosphorylation
alters its function.
Binding partners
RhoU and RhoV have been reported to interact with sev-
eral proteins (Figure 2 and 3), of which the PAKs are the
Figure 3. RhoV domain structure and protein interactions. RhoV has a core GTP-binding domain (blue) and N- and C-terminal extension
regions (gray). The RhoV C-terminus has a CFV motif (amino acids 234–236) which is modiﬁed on the cysteine by palmitoylation. p21-
activated kinases (PAKs) are well established effector proteins that bind to the effector loop (yellow), and mediate some of the functions
of RhoV. RhoV has been reported to interact with PAK1, PAK2 and PAK6, although it has only been shown to activate PAK1. PAK2 inter-
action also requires the C-terminal extension. RhoV can regulate apoptosis in a JNK-dependent manner. The interaction with JNK has
not been characterized biochemically, although deletion of the N-and C-terminal regions reduces JNK phosphorylation.
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best-characterized. PAKs are serine/threonine-speciﬁc
intracellular protein kinases that are involved in a variety
of cellular responses, including changes in cell morphol-
ogy, motility, survival and gene transcription, and are
well known targets for Cdc42 and Rac1. RhoU activates
PAK13,6, and mutations in RhoU affect both its ability to
bind to the PAK1 CRIB domain and to increase PAK1
autophosphorylation.3,5 RhoU also interacts with PAK4,
although it appears to use different residues to interact
with PAK4 compared with PAK115 (Figure 4). Phospho-
PAK4 (pS474) levels are unchanged upon RhoU overex-
pression, indicating that PAK4 is not a RhoU effector
protein.15 Instead, PAK4 plays an unconventional
kinase-independent role in RhoU regulation. PAK4 reg-
ulates RhoU expression levels by protecting RhoU from
Rab40A-mediated proteasomal degradation.15 RhoU sta-
bilization by PAK4 leads to stimulation of MDA-MB-
231 breast cancer cell migration and promotes focal
adhesion turnover.15
PAK2 and PAK6 have been shown to bind RhoV by
co-immunoprecipitation analysis.4,16 Both PAK2 and
PAK6 binding was increased by introduction of an acti-
vating mutation, RhoV-G40V, whereas binding was
abolished with a RhoV-S45N dominant negative
mutant.4,16 The C-terminal region of RhoV was neces-
sary to mediate the interaction with PAK2, but the role
of RhoV effector loop residues (switch I) was not investi-
gated.4 On the other hand, RhoV was demonstrated to
interact with the PAK6 CRIB motif using speciﬁc resi-
dues in its effector loop (T63, L65 and E66) (Figure 4),
but the role of the N- and C-terminal extension regions
was not tested. Interestingly, RhoV overexpression did
not increase phospho-PAK6 (pS560) levels, suggesting
that PAK6 is not a RhoV effector protein,16 similar to
the observations with RhoU and PAK4.15 It would there-
fore be interesting to test whether PAK6 regulates RhoV
stability.
As mentioned previously, the N-terminal region of
RhoU contains 3 proline-rich motifs (PRMs). By con-
trast, RhoV does not contain PRMs in its N-terminal
extension. The sequences in RhoU are PAFPDR (resi-
dues 8–13), PPVPPRR (20–26) and PGEPGGR (36–42)
(Figure 4). The N-terminal region of RhoU binds to vari-
ous SH3-domain containing adaptor proteins, including
Grb2,5,14 Nck25,6 and phospholipase Cg.5 Peptide analy-
sis has revealed that the central PxxP motif is responsible
for mediating the interaction with Grb2 and Nck2.17 The
interactions with Grb2, Nck2 and phospholipase Cg are
direct5 and are mediated by the PRMs located in the N-
terminal region.6,14 Grb2 has been shown to couple
RhoU to epidermal growth factor (EGF) receptor signal-
ing, and RhoU co-localizes with the EGF receptor on
endosomes after EGF stimulation.14 This allows RhoU to
link to receptor tyrosine kinases and participate in down-
stream signaling cascades. It has been hypothesized that
the binding of the adaptor proteins relieves the
Figure 4. RhoU and RhoV effector protein interactions. (A) Human RhoU and RhoV protein sequences were aligned using the Clustal
Omega pairwise sequence alignment tool (EMBL-EBI). Identical amino acids in the 2 sequences are indicated by a line, similar by 2 dots,
and non-conserved by a dot. Proline-rich motifs in RhoU and speciﬁc residues that have been reported to interact with PAK6 (RhoV) are
highlighted and boxed. The RhoU effector loop (asterisk-labeled box) is magniﬁed in (B) and the residues responsible for interaction
with the indicated effector proteins are highlighted. Mutation of T81, F83 and F86 in RhoU prevents PAK1 interaction but does not pre-
vent interaction with PAK4. This indicates that distinct residues in the effector loops of RhoU and RhoV are responsible for the interac-
tion with different PAK proteins. PRMs; proline-rich motifs; T, Thr; F, Phe; P, Pro.
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inhibitory roles of the N-terminal regions and promotes
RhoU effector activation.5 Nck2 has also been shown to
interact with PAK1, and thus it is possible that Nck2
serves to mediate the interaction between RhoU and
PAK1 in cells.6
RhoU also associates with the non-receptor tyrosine
kinase Pyk2, which requires the N-terminal region of
RhoU.18 However, Pyk2 does not contain an SH3
domain, thus the interaction is unlikely to involve the
PRMs, and it is unclear how Pyk2 interacts with RhoU.
The FERM domain of Pyk2 was suggested to mediate the
RhoU interaction, as well as speciﬁc residues in the
RhoU effector loop (P80, F83 and F86) (Figure 4). Fur-
thermore, Pyk2 was required for RhoU to induce the for-
mation of ﬁlopodia. Src-mediated phosphorylation
promoted the formation of the RhoU-Pyk2 complex and
the subsequent activation of Pyk2,18 although whether
this involves the RhoU C-terminal Src phosphorylation
site Y254 (see above) is not known. Of note, Pyk2 might
also phosphorylate RhoU, although the function of this
phosphorylation event is unclear.
RhoU is speculated to be insensitive to GEFs due to its
rapid guanine nucleotide exchange rate, but it could be
regulated by GAPs. Indeed, RhoU co-immunoprecipi-
tates with ARHGAP30 and CdGAP.19 Similar to RhoU
overexpression, ARHGAP30 stimulated the formation of
ﬁlopodia and stress ﬁber disassembly,19 suggesting that
ARHGAP30 is downstream of RhoU signaling and that
RhoU might stimulate ARHGAP30 activity.
Functions of RhoU
Cellular studies
RhoU overexpression has a striking effect on cell mor-
phology and actin dynamics in a variety of cell models,
although the effects appear to be cell-type dependent.
RhoU is involved in promoting focal adhesion turnover,
decreasing stress ﬁbers , inducing ﬁlopodia and/or regu-
lating cell adhesion in several cell types,15,18,20 but the
mechanism underlying these RhoU-induced responses is
not clear. In an osteoclast model, RhoU localized to
podosomes, but not focal adhesion complexes, and this
was dependent on the C-terminal region. RhoU was also
demonstrated to increase the adhesion and migration of
osteoclast precursor cells.21 In NIH3T3 ﬁbroblasts, acti-
vated RhoU resulted in a signiﬁcant loss of focal adhe-
sions.22 In HeLa cells, RhoU also localized to focal
adhesions and promoted their disassembly during cell
migration.20 Conversely, siRNA-mediated knockdown of
RhoU resulted in the reduced adhesion of T-ALL cell
lines to ﬁbronectin and to endothelial cells.23 This indi-
cates that the role of RhoU in cell-substratum or cell-cell
adhesion is cell-type dependent. However, another inter-
pretation is that RhoU only reduces the assembly of large
focal adhesion complexes, and since T-cells do not have
focal adhesions it could have a different function in regu-
lating adhesion in these cells.
RhoU has recently been reported to increase paxillin
phosphorylation in MDA-MB-231 breast cancer cells.15
Paxillin is a scaffolding component in focal adhesion com-
plexes and serves as a platform to integrate adhesion sig-
naling.24 RhoU overexpression increased phospho-paxillin
(pS272) levels in a PAK4-depleted background, and RhoU
associated with paxillin.15 RhoU might provide a scaffold
to recruit an additional kinase to induce paxillin S272
phosphorylation, possibly via JNK activation.3,20
RhoU has been implicated in regulating apicobasal epi-
thelial cell polarity due to its ability to bind the polarity pro-
tein PAR6 via its effector loop (Figure 2).25 RhoU localized
to the apical and basolateral membranes in MDCK epithe-
lial cells and an activating RhoU-Q107L mutant was
described to inhibit tight junction formation. Furthermore,
a mutation in the RhoU effector loop prevented binding to
PAR6 and was unable to delay tight junction formation,
whereas the N-terminal extension was not required for this
response. Cdc42 is well known to bind to PAR6 and stimu-
late apicobasal polarity26 but the effects and localization of
RhoU in epithelial cells appear different to Cdc42, and thus
direct comparison of the roles of the 2 Rho GTPases in epi-
thelial polarity would be useful.
In vivo studies
There is mounting evidence that RhoU regulates the
polarity and architecture of cells during developmental
processes.27-29 It contributes to the formation of cell-cell
junctions between zebraﬁsh cardiomyocytes through a
pathway involving the GEF Arhgef7b and PAK1, thereby
affecting cardiac morphogenesis.27 It would be interest-
ing to determine whether PAR6 is involved in RhoU
signaling in zebraﬁsh cardiomyocytes, similar to its role
in MDCK epithelial cells.25 In C. elegans, the RhoU/
RhoV ortholog CHW-1 (which is equally similar to
RhoU and RhoV) contributes to establishing polarity in
vulval precursor cells (VPCs) during vulval develop-
ment.28 Although loss of chw-1 alone did not alter vulval
development, it modulated the effects of 2 different Wnt
receptors on VPC polarity,28 which might reﬂect its role
as a Wnt-inducible gene.3
RhoU also plays a role in regulating the development
of the mouse foregut.29,30 RhoU is expressed during
embryogenesis in the epithelium of the developing gut.
Once the epithelium becomes multi-layered RhoU
expression decreases. Using embryos from RhoU-
depleted embryonic stem cells, it was found that RhoU is
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required for epithelial morphogenesis. RhoU-depleted
cells had fewer apical microvilli and a reduction in sub-
apical ﬁlamentous actin levels. This indicates that RhoU
is important for epithelial architecture,29 consistent with
results in vitro with MDCK cells.25
Apart from the regulation of cell adhesion and cell shape
during development, RhoU plays a role in cell migration in
developmental models. Over-expression of the C. elegans
RhoU/RhoV ortholog CHW-1 disrupted migration of
gonadal distal tip cells,27 a well-characterized migration
model in C. elegans.31 In addition, RhoU is required for the
migration of cranial neural crest cells in Xenopus laevis
embryos.32 RhoU also regulates the ability of these cells to
differentiate into craniofacial cartilages.32
Functions of RhoV
Cellular studies
RhoV overexpression induces ﬁlopodia and lamellipodia
in several different cell types.4,33 RhoV overexpression
also induced the formation of focal adhesion complexes
and localized to these sites in an endothelial cell line.33
This contrasts to the disassembly of focal adhesions stim-
ulated by RhoU.
RhoV has been reported to activate the JNK MAPK
kinase cascade in several studies.4,34 RhoV appears to
stimulate the apoptosis of PC12 cells via activation of
JNK and the death receptor-mediated and mitochondrial
apoptotic pathways.34 RhoV mRNA expression increases
as macrophages differentiate into osteoclasts, coinciding
with a high level of apoptosis,35 but whether RhoV is
responsible for this apoptosis is not known.
RhoV has an unconventional effect on PAK1. RhoV,
as well as Cdc42, has been shown to stimulate the ubiqui-
tination and proteasome-mediated degradation of PAK1
in Jurkat T- cells.36 RhoV interaction with and activation
of PAK1 appears to be required for its degradation, based
on the effects of RhoV on a range of PAK1 mutants Fur-
thermore, both N-terminal and C-terminal extension
regions of RhoV were required to trigger PAK1 degrada-
tion, and the N-terminal region was required for PAK1
degradation but not its activation. This suggests a second
unknown function for RhoV in PAK1 degradation.36
In vivo studies
RhoV has been described to be involved in developmen-
tal processes, although its function appears to differ from
RhoU. For example, RhoU and RhoV have different
functions in neural crest cells in Xenopus laevis.37 RhoV
expression is transiently induced during neural crest dif-
ferentiation by the canonical Wnt pathway. RhoV
depletion inhibited the expression of neural crest
markers such as the transcription factors Sox9, Slug and
Twist and blocked differentiation. Conversely, RhoV
overexpression induced expansion of the neural crest
domain.38 On the other hand, RhoU is induced later by
the non-canonical Wnt pathway and contributes to neu-
ral crest migration, as described above.
RhoV plays a role in maintaining E-cadherin at adhe-
rens junctions during zebraﬁsh gastrulation.39 During
gastrulation, the zebraﬁsh embryo undergoes a series of
morphological changes to form the 3 distinct germ
layers: endoderm, mesoderm and ectoderm. E-cadherin-
mediated cell-cell adhesion is essential during this pro-
cess. RhoV depletion induced a strong phenotype in
zebraﬁsh gastrulation, similar to that induced by E-cad-
herin depletion. It reduced E-cadherin levels at cell-cell
junctions, as well as phospho-PAK localization at these
regions. PAK interacts with the Rac/Cdc42 GEF b-PIX,
and depletion of b-PIX induced a similar gastrulation
phenotype to RhoV depletion, suggesting that RhoV acts
via PAK and b-PIX to localize E-cadherin.39 So far RhoV
has not been reported to affect E-cadherin localization in
cultured cells in vitro, and thus this would be an interest-
ing area for future research.
Conclusions and future perspectives
Despite the sequence similarity between RhoU and RhoV,
they have several different functions in mammalian cells in
vitro and in model organisms. So far, however, little is
known of the molecules that activate RhoU and RhoV dur-
ing developmental processes or cellular responses in vitro.
Further information on post-translational modiﬁcations
and the roles of known or yet-to-be-identiﬁed interacting
partners in regulating their activity is needed. For example,
it is unclear whether they are downregulated by GAPs or
stimulate GAPs to act on other Rho GTPases. There is little
evidence yet that implicates these proteins in cancer pro-
gression. However, RhoU has been described to be upregu-
lated in T-cell acute lymphoblastic leukemia (T-ALL)23 and
RhoV is upregulated in non-small cell lung cancer.40 Their
roles in regulating cell migration and cell adhesion in vitro
and in vivo make them potential targets in cancer
progression.
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